SUB CATEGORIES Short term |  Life |  Legal |  Employee Benefits |  General |  Technology |  Investments / Economy |  Healthcare | 

BAT: still smoking amid COVID-19 volatility

15 May 2020 Sanlam Private Wealth
David Lerche, Senior Investment Analyst at Sanlam Private Wealth

David Lerche, Senior Investment Analyst at Sanlam Private Wealth

Excluding gold shares, British American Tobacco (BAT) has delivered the second-highest return of the JSE Top 40 constituents (behind Naspers, the largest single-stock exposure in our portfolio) and outperformed the JSE All Share Index (ALSI) by 27% year to date. The stock has also outperformed the UK’s FTSE 100 Index by 15% year to date.

When we increased our exposure to BAT 16 months ago in January 2019, the stars aligned to present us with an opportunity to buy a predictable, defensive business whose fortunes are independent of the South African environment, at a highly attractive valuation. This took the company to the largest overweight position in our houseview portfolio relative to the ALSI benchmark. Since then, the stock has delivered a total rand return of 63%.

We’ve always liked the company’s low correlation to the rest of the South African market. Unlike the other large-cap, rand-hedge stocks on the JSE, three quarters of BAT’s business is in developed markets. This means that at times of stress and emerging market currency weakness, as is currently the case, BAT’s business is less affected than others and its correlation to the JSE decreases. In contrast, Anheuser-Busch InBev, the other global staples player listed on the JSE, is predominantly an emerging market business whose correlation to the local market increases during times of emerging market stress.


Over the past two months, most companies that had previously given earnings or operations guidance to the market have retracted such guidance given the uncertainties around the impact of COVID-19. In stark contrast, BAT’s management recently reiterated guidance for ‘high single-figure, adjusted constant-currency earnings per share (EPS) growth’. This illustrates the stability of the group’s revenues.

There’s no doubt that BAT will be affected by the pressures on the global economy, but the impact will be less than it’s likely to be on other companies. BAT makes half of its operating profit in the US, and thus benefits from the strength of the US dollar. Unlike South Africa, most countries haven’t banned the sale of cigarettes during their lockdown periods.

During the financial crisis of 2008 and 2009, BAT’s earnings growth slowed, but it remained positive. Even in 2009, its worst year, the group grew EPS at 9% in constant currency terms (+19% as reported in GBP). We expect the situation in the current crisis to be similar: growth should slow, but remain positive.

BAT was one of the few companies whose profitability improved through the financial crisis, with the operating margin rising smoothly from 30% in 2007 to 34% in 2010. While we don’t expect a repeat of that expansion over the coming years, we retain our view that BAT should be able to deliver consistent small increases in margins.


As we’ve written before, there’s substantial value in having an addicted customer base. Higher prices can offset volume declines. BAT’s strategy continues to evolve to suit changing attitudes towards smoking, with management supporting a leaner, more agile organisation that’s driving the shift towards less harmful nicotine alternatives.

While the group’s debt is relatively high at four times 2019 earnings before interest, tax, depreciation and amortisation (EBITDA), this business is easily able to handle such gearing. BAT recently reiterated its commitment to paying out 65% of profits as dividends at a time when many companies have suspended shareholder distributions, which illustrates the group’s ability to convert accounting profits into cash.

The above factors, particularly the high earnings visibility compared to other stocks, are well-known and now largely reflected in the price. This means that the BAT valuation appears more rational than that of many other companies.

From a South African investor’s perspective, on top of BAT’s valuation – relative to other opportunities – not looking quite as enticing, the rand is looking particularly cheap at around three standard deviations away from its long-run fitted purchasing power parity (PPP) valuation. The risks are substantially skewed towards future rand strength, which would be negative for the BAT price in our currency.


Having enjoyed the ride as the market appreciated and gave credit for the company’s strengths over the past 16 months, we now face a pleasant problem: BAT’s outperformance means that its weight in our houseview portfolio has reached uncomfortable levels from a single-stock, risk-management perspective.

While BAT remains a core holding in our client portfolios, we now have the opportunity to recycle a portion of the profits from this outperformance towards companies that the market isn’t valuing rationally, or in terms of which the market is not looking through the cycle.

Quick Polls


ASISA’s lobbying of the SARB to suspend Circular 15, which contained significant changes to foreign exchange controls. What is your take on this accusation?


[a] ASISA was right to seek clarity on Circular 15
[b] Large asset managers are conflicted & will suffer financially if Circular 15 stands
[c] Savers get enough exposure to offshore assets under existing Reg 28
[d] Who cares?
fanews magazine
FAnews November 2020 Get the latest issue of FAnews

This month's headlines

Customer experience in the ‘now’ generation
Is our industry a tainted industry?
How to keep brokers out of the firing line
Getting to grips with contractual versus delictual liability
International trusts and tax consequences
The COVID-19 pandemic and medical schemes
Subscribe now